Microvesicles releasing by oral cancer cells enhance endothelial cell angiogenesis via Shh/RhoA signaling pathway. Issue 10 (3rd October 2017)

• Record Type: Journal Article
• Authors: Huaitong, Xiao; Yuanyong, Feng; Yueqin, Tao; Peng, Zhao; Wei, Shang; Kai, Song
• Is Part Of: Cancer biology & therapy. Volume 18:Issue 10(2017)
• Page Start: 783
• Page End: 791
• Publication Date: 2017-10-03
• Subjects: angiogenesis -- endothelial cells -- Gli1 -- Oral cancer -- microvesicles -- Shh -- RhoA; 616.99406
• DOI: 10.1080/15384047.2017.1373213
• Languages: English
• ISSNs: 1538-4047

Abstract

ABSTRACT: The present study aimed to investigate the significance of hedgehog signaling pathway in association with clinicopathology parameters and its effect on angiogenesis in oral squamous cell carcinoma (OSCC). The expression of Sonic Hh (Shh) and Gli1 were done on primary tumors and metastatic lymph nodes in OSCC samples from 80 patients by immunohistochemical analysis. The western blot was used to examine the expression of Shh in OSCC cell lines and OSCC-derived microvesicles (MVs). The role of Shh carried by MVs to induce endothelial cell angiogenesis was further investigated by matrigel assay. Our results indicated that the expression of Shh was positive associated with microvesseldentisty(MVD), TNM stage, tumor recurrence and lymph node metastasis. Moreover, Shh and Gli1 expression were higher in paired metastatic lymph nodes compared with expression of their primary tumors. The expression of Shh was abundant in Cal27, and present in SCC4, SCC9, and the amount of Shh protein in Cal27 targeting MVs was increased significantly than Cal27 cell group, up to ∼ fifth-fold. The Cal27 derived MVs increased significantly angiogenesis of HUVECs in vitro, and this effect was blocked with exoenzyme C3 transferase (C3) and shRNA targeting RhoA by suppressing RhoA expression and activation. The data suggested that OSCC derived Shh carried by MVs may facilitate the tumor growth and modulate the preparation of a vascular network in primary tumor and/or premetastatic niche.